|Mr. Paul Baehr||Pres, CEO & Chairman||313.6k||N/A||1943|
|Mahendra Kumar Pallapothu||VP of Operations||293.34k||N/A||N/A|
|Belinda Franco C.A., CPA||CFO, Director of Fin. & Admin. and Sec.||N/A||N/A||N/A|
IBEX Technologies Inc., through its subsidiaries, manufactures and markets enzymes for biomedical use in Canada, the United States, the United Kingdom, and internationally. It offers a portfolio of recombinant glycosaminoglycan lyases, including Heparinase I, Heparinase II, Heparinase III, Chondroitinase AC, and Chondroitinase B; cartilage assays for the study of synthesis and degradation of connective tissue components; collagen antibodies; and diamine oxidase liquid. The company also manufactures and markets a range of arthritis assays, which are used in osteoarthritis research. In addition, it provides services, such as filling and lyophilization for making disposable medical device components; and custom fermentation and micro dispensing of enzymes, as well as contract manufacturing. It serves manufacturers of medical devices, quality control labs, and academic research institutions. IBEX Technologies Inc. was founded in 1986 and is based in Montreal, Canada.
IBEX Technologies Inc.’s ISS Governance QualityScore as of April 30, 2021 is 5. The pillar scores are Audit: 10; Board: 2; Shareholder Rights: 7; Compensation: 1.